NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Management — NMD Pharma
NMD Pharma - Capnova
NMD Pharma — NMD Pharma
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma raises $47M in series A investment round from INKEF and existing investors, to advance treatments of neuromuscular disorders | Nordic 9
Labiotech.eu on Twitter: "NMD Pharma, from @AarhusUni, is willing to tackle Neuromuscular Transmission Disorders #BioEquity2016… "
Management — NMD Pharma
NMD Pharma A/S | LinkedIn
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis | MENAFN.COM
NMD Pharma Information | NMD Pharma Profile
NMD Pharma, finalist i Life Sciences kategorien - EY Danmark
Detailed Description | NMD-GPS
NMD Pharma picked as Biotech of the Week by Labiotech.eu — NMD Pharma
Klaus Wilhardt - Corporate identity, Design, Logo/navnetræk og designguides
Big deal: NMD flexes series A muscles - Global University Venturing
Company Presentation
Investors — NMD Pharma
Neuromuscular Drug Development Summit (NMD) - Pharma Journalist
NMD Pharma
